Myoepithelioma of the soft tissues is a rare entity and little is known about how best to manage locally recurrent and high-grade disease. Here, we retrospectively examined outcomes of surgery, chemotherapy, and radiation therapy (RT) for treatment of low-grade and high-grade myoepithelioma of soft tissues.
We reviewed 20 cases of myoepithelioma of soft tissues seen at Mayo Clinic between 1994 and 2014. The effect of histologic grade and therapies received on relapse and survival were assessed.
We identified 13 patients with low-grade disease and 7 patients with high-grade disease. We found that low-grade disease was frequently effectively managed with surgical resection alone, whereas high-grade disease frequently metastasized and was often fatal. The 5-year event-free survival was 88% (confidence interval, 46%-98%) for low-grade disease versus 36% (confidence interval, 7%-75%; P=0.04) for high-grade disease. The relapse rate in low-grade disease was 29% at 5 years versus 64% (P=0.04) in high-grade disease. No significant responses to chemotherapy were noted, however, excellent responses to perioperative RT were seen.
Surgery continues as the primary modality of treatment for myoepithelioma of soft tissues. Our study did not show a clear benefit of chemotherapy in the metastatic disease setting, but supports the use of perioperative RT in the management of high-grade disease; further investigation is warranted.
*Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis
Departments of †Medical Oncology
‡Laboratory Medicine and Pathology
∥Orthopedic Surgery, Mayo Clinic, Rochester, MN
Supported by the Clinician Investigator Training Program, Mayo Clinic, and Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS).
The authors declare no conflicts of interest.
Reprints: Evidio Domingo-Musibay, MD, Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street S.E., MMC 480, Minneapolis, MN 55455. E-mail: email@example.com.